Larvol Delta - A-Study-of-JSB462-Luxdegalutamide-Plus-Lutetium-177Lu-Vipivotide-Tetraxetan-in-Patients-With-Metastatic-Castration-Resistant-Prostate-Cancer-mCRPC

luxdegalutamide (ARV-766) - Novartis

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) - Novartis

http://clinicaltrials.gov/ct2/show/NCT07047118

Apr 22, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next